Research Article
Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients
Table 1
Summary of pathology findings correlated with recurrence score (RS).
| | | Low RS (0–17)
| Intermediate RS (18–30)
| High RS (≥31)
| p value |
| | SIZE | 1.4 cm | 1.3 cm | 1.2 cm | 0.997 | | Estrogen receptor+ | 100% (100%) | 100% (100%) | 99.8% (100%) | 0.99 | | Progesterone receptor+ | 97.5% (97.5%) | 76.0% (88.3%) | 40.8% (61.2%) | <0.001 | | HER2Neu | 0% (0%) | 0% (1.95%) | 12.2% (26.5%) | <0.001 | | Nottingham (3–5) | 19.7% | 8.3% | 0% | <0.001 | | Nottingham (6-7) | 67.3% | 68.9% | 34.3% | <0.001 | | Nottingham (8-9) | 13% | 22.8% | 66.7% | <0.001 | | Tubular ± lobular | 16.4% | 8.9% | 0% | <0.001 | | Invasive lobular cancer, pleomorphic | 17.4% | 21.7% | 19.3% | 0.790 | | Invasive lobular cancer, histiocytoid | 2.7% | 7.2% | 1.8% | 0.110 | | Micropapillary | 14.7% | 16.7% | 24.6% | 0.233 | | Mucinous | 4.7% | 4.4% | 3.5% | 0.913 | | Anaplastic | 0% | 1.7% | 7.0% | 0.010 | | Lymphatic invasion | 24.1% | 18.9% | 22.8% | 0.716 | | Ductal carcinoma in situ, comedo type | 3.3% | 6.1% | 15.8% | 0.006 |
|
|
Oncotype DX score (in house score).
|
